Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Zoledronic acid prevents bone loss in hormone-treated breast cancer patients
January 20th, 2005
Zoledronic acid prevents loss of bone mass caused by adjuvant treatment with an aromatase inhibitor or tamoxifen and the luteinising hormone-releasing hormone analog (LHRHa) goserelin in premenopausal women with early-stage hormone receptor-positive breast cancers. This new clinical finding was presented at the annual San Antonio Breast Cancer Symposium. For the first time, a large multicenter clinical trial has shown how to prevent cancer treatment-induced bone loss (CTIBL) and established that such bone loss is a frequent side effect of hormonal therapy for breast cancer in premenopausal women. The study is sponsored by the Austrian Breast and Colorectal Cancer Study...
Source: Women's Health Weekly (2005-01-20)
|
